Celularity Inc CELU revenue by segment, product and geography
In its fiscal year ending 2025-12-31, Celularity Inc reported revenue across 3 business segments; the largest, Degenerative Disease, was $17.3M, 65.2% of the filed sum (-64.2% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Degenerative Disease$17.3M65.2%-64.2% yoy
- Biobanking$5.43M20.5%+5.7% yoy
- Cell Therapy$3.81M14.3%+453.3% yoy
Members sum to the consolidated $26.6M for this period.
- Product$13.2M49.6%-62.7% yoy
- License Royalty And Other$7.94M29.9%-42.2% yoy
- Service$5.43M20.5%+5.7% yoy
Members sum to the consolidated $26.6M for this period.
- Degenerative Disease$2.24M42.5%no prior
- Cell Therapy$1.59M30.1%no prior
- Biobanking$1.45M27.4%no prior
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.